Table 2

 Characteristics of rofecoxib study subjects (n = 16)*

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HbCO, carbomonoxyhaemoglobin; PEF, peak expiratory flow; FEF25–75, mid forced expiratory flow.
*Data refer to patients who completed the study and are expressed as mean (SE).
†All the patients had a smoking history of more than 10 pack years.
‡Atopy was an exclusion criterion. Absence of atopy was confirmed by skin prick testing.
¶All values are <2.6%. One patient was excluded from the study because of recent smoking exposure on visit 3 (HbCO 4.6%) and COPD exacerbation.
Age (years)68 (2)
Arterial HbCO (%)0.7 (0.2)¶
Pack years>10
FEV1 (l)1.51 (0.11)
FVC (l)2.82 (0.18)
FEV1 (% pred)59.6 (3.4)
FVC (% pred)85.8 (3.8)
FEV1/FVC (%)54.4 (2.6)
PEF (l/s)4.25 (0.34)
PEF (% pred)58.7 (4.2)
FEF25–75 (l/s)0.58 (0.07)
FEF25–75 (% pred)19.4 (2.5)
Change in FEV1 post-bronchodilator (% pred)2.2 (1.4)
    β2 agonists5